The results of testing growth hormone (GH) reserve using human pancreatic growth hormone-releasing factor 1-44 amide (hp GRF 1-44 amide) have been compared with the GH responses in a variety of other dynamic tests in seven acromegalic patients. The GH release following hp GRF 1-44 amide correlated with the GH suppression following bromocriptine, but showed an inverse correlation with the GH release following stress tests (insulin-induced hypoglycaemia/glucagon). There was no correlation between the GH responses in these three tests and any of the other tests: TRH, GnRH and glucose. A hypothesis is proposed to explain these findings on the basis of varying degrees of GH secretion from adenomatous and normal pituitary somatotrophs in acromegaly.
Introduction
In addition to basal hypersecretion of growth hormone (GH), acromegalics frequently display aberrant GH responses to various stimuli. These include failure of suppression following glucose, failure of stimulation during insulin-induced hypoglycaemia, paradoxical stimulation with thyrotrophin releasing hormone (TRH) and, less often, gonadotrophin releasing hormone (GnRH) and suppression of GH secretion with bromocriptine. As the vast majority of acromegaly is due to clearly identifiable pituitary adenomas these findings are commonly attributed to abnormal receptors on the tumorous somatotrophs. Very bromocriptine (P = 0.014, Spearman's rank correlation coefficient) (Figure 1 ). There was an inverse correlation between the peak increments in GH posthp GRF 1-44 amide and 'stress' (insulin-induced hypoglycaemia/glucagon) (Figure 2 ) (P<0.01). No other correlations were demonstrable.
All seven subjects showed increases in GH following 50 #g hp GRP 1-44 amide i.v. (Table I ). In four cases there was a minor early peak at 30 minutes and a later larger peak at 120 minutes, in two cases single late peaks at 90 and 120 minutes respectively and in one case only a single early peak at 30 minutes.
The findings in all six tests with respect to the maximum change in GH concentration observed are summarized in Table II . It should be stated that the minimum GH concentration following oral bromocriptine occurred at 2 hours or more after the dose.
The peak increment in GH post-hp GRF 1-44 amide correlated with the maximum decrement post-
Discussion
This study disclosed variable GH responses to 50 fig hp GRF 1-44 amide in acromegaly as we previously demonstrated with the same dose in normal volunteers.6 In contrast to those findings, however, in six out of seven acromegalics the peak level was attained later than in normal subjects, although there was a minor early peak in four subjects. The GH response to TRH encompassed the greatest range, from nil to greater than 1234 mU/l but these changes showed no relationship to those seen in other tests in contrast to the earlier suggestions of a correlation with suppression after bromocriptine.7 The absence of a correlation between the changes in GH following hp GRF 1-44 amide and oral glucose is an extension of our previous findings in two acromegalics and in contradiction of the claims by Wood and colleagues.8 Our findings, insofar as the tests and patients are comparable, are not dissimilar to those reported elsewhere.9" 0"'2 There is a striking discordancy between our findings suggesting that the greater the release of GH post-hp GRF 1-44 amide, the greater suppression after bromocriptine and the opposite of the assertion by Chiodini et al."3 Their relationship was considerably weaker but was based on the study of 35 patients. Their data are expressed as percentage changes but reanalysing it in terms of absolute concentration differences merely abolishes the pattern and does not reverse it. They do not say if any patient had received any form of treatment except seven who had previously received bromocriptine. The single difference between the present study and most others published is that of dosage. The use of a submaximal dose (50 jig as opposed to 100 pg) might allow subtle differences in secretion to be observed (S. Reichlin, personal communication).
The following hypothesis is proposed to account for the observations made in this study. The normal pituitary somatotrophs secrete GH under the dual control of hypothalamic GRF and somatostatin which in turn are influenced by various neural inputs, including stress, and mediated by a variety of neurotransmitters, including dopamine; exogenous GRF largely reaches the pituitary by the portal vessels and bromocriptine largely acts centrally (Figure 3a) . The adenomatous tissue in acromegaly is partly autonomous and often has a significant blood supply from capsular and trabecular vessels. Hypothalamic GRF production in rats is reduced by intracisternal GH, suggesting a short feedback loop.'4 The exogenous administration of hp GRF 1-44 amide tends to produce an early peak of GH from normal pituitary cells -reached via portal vessels and reduced in height b GH Figure 3 Model for the endogenous and exogenous control ofGH secretion (a) from the normal anterior pituitary, (b) in acromegaly due to hypersecretion of GH from a pituitary adenoma -which (i) exerts a negative feedback action on endogenous GRF production and (ii) is partly reached in a delayed fashion, by non-portal blood vessels.
-60 L -UV group.bmj.com on July 4, 2017 -Published by http://pmj.bmj.com/ Downloaded from because of relatively suppressed activity induced by the feedback inhibition of endogenous GRF by GH from the adenoma. This central inhibition ofendogenous GRF secretion is also responsible for the relatively obtunded !stress release of GH and the failure of bromocriptine to act centrally to release GH. Instead there is direct action on exogenous hp GRF 1-44 amide and bromocriptine on the adenomatous tissue, in part poorly penetrated and reached by non-portal vessels. Hence the response from the adenoma to hp GRF 1-44 amide and bromocriptine are both delayed (Figure 3b ). This explanation is highly speculative and requires further studies for confirmation with greater numbers ofsimilarly treated patients. 
